AI Verdict
PBYI has stronger fundamentals based on our AI analysis.
PBYI vs PBHC Fundamental Comparison
| Metric | PBYI | PBHC |
|---|---|---|
| Revenue | $228.4M | $76.7M |
| Net Income | $31.1M | $-1.9M |
| Net Margin | 13.6% | -2.5% |
| ROE | 23.9% | -1.6% |
| ROA | 14.4% | -0.1% |
| Current Ratio | 2.00x | N/A |
| Debt/Equity | 0.17x | 0.11x |
| EPS | $0.61 | $0.47 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PBYI vs PBHC: Frequently Asked Questions
Is PBYI or PBHC a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), PBYI has stronger fundamentals. PBYI is rated BUY (72% confidence) while PBHC is rated SELL (45% confidence). This is not investment advice.
How does PBYI compare to PBHC fundamentally?
PUMA BIOTECHNOLOGY, INC. has ROE of 23.9% vs Pathfinder Bancorp, Inc.'s -1.6%. Net margins are 13.6% vs -2.5% respectively.
Which stock pays higher dividends, PBYI or PBHC?
PBYI has a dividend yield of N/A or no dividend while PBHC has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PBYI or PBHC for long term?
For long-term investing, consider that PBYI has BUY rating with 72% confidence, while PBHC has SELL rating with 45% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PBYI vs PBHC?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PBYI vs PBHC, the AI consensus favors PBYI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.